INFORMATION FOR HEALTH PROFESSIONALS
Home | Consumers | Health Professionals | Regulatory | Other | Hot Topics | Search
Home | Consumers | Health Professionals | Regulatory | Other | Hot Topics | Search
Website: March 2011
Prescriber Update 2010; 32(1):9
A new medicines monitoring scheme, M2, has been launched to promote reporting of adverse reactions to specific medicines of interest.
Stimulating reporting of specific reactions to specific medicines helps CARM and Medsafe to investigate possible safety signals further, decide if there is a causal relationship, and take action if necessary.
M2 has been developed in collaboration with the MARC and CARM. Further information about the scheme can be found on the Medsafe website at: http://www.medsafe.govt.nz/profs/M2MedicinesMonitoring.asp
An evaluation of the safety signal at the conclusion of the monitoring period will be published on the Medsafe website. The medicines and reactions that are being monitored are listed below.
WE NEED YOUR HELP!
Please send your reports for these potential safety issues* listed in the table below.
| Medicine | Potential safety issue | Active monitoring period ends* |
|---|---|---|
| Rivaroxaban | Atrial fibrillation | 1 Sept 2011 |
| Simvastatin | Joint pain and swelling | 1 Sept 2011 |
| Quetiapine | cardiomyopathy | 1 Sept 2011 |
is a new scheme designed to
collect more information on potential safety signals for specific medicines.
Safety signals are identified from reports of adverse medicine reactions sent to the Centre for Adverse Reactions Monitoring (CARM). For further information see the Medsafe website
The scheme does not replace
routine adverse reaction reporting. Find out how to report at:
http://www.otago.ac.nz/carm or http://www.medsafe.govt.nz
